Maximilian Y. Emmert

Dr. Maximilian Y. Emmert


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2017 in npj Regenerative Medicine
Verified
Journal Article
Open access
PDF file
ECElena Cambria
Elena Cambria
FPFrancesco Pasqualini
Francesco Pasqualini
PWPetra Wolint
Petra Wolint
JGJulia Günter
Julia Günter
JSJulia Steiger
Julia Steiger
MEMaximilian Y. Emmert
Maximilian Y. Emmert
Acute myocardial infarction and chronic heart failure rank among the major causes of morbidity and mortality worldwide. Except for heart transplantation, current therapy options only treat the symptoms but do not cure the disease. Stem cell-based therapies represent a possible paradigm shift for cardiac repair. However, most of the first-generation approaches displayed heterogeneous clinical outcomes regarding efficacy. Stemming from the desire to closely match the target organ, second-generation cell types were introduced and rapidly moved from bench to bedside. Unfortunately, debates remain around the benefit of stem cell therapy, optimal trial design parameters, and the ideal cell type. Aiming at highlighting controversies, this article provides a critical overview of the translation of first-generation and second-generation cell types. It further emphasizes the importance of understanding the mechanisms of cardiac repair and the lessons learned from first-generation trials, in order to improve cell-based therapies and to potentially finally implement cell-free therapies.

1 December 2011 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
MEMaximilian Y. Emmert
Maximilian Y. Emmert
BSBurkhardt Seifert
Burkhardt Seifert
MWMarkus Wilhelm
Markus Wilhelm
JGJürg Grünenfelder
Jürg Grünenfelder
VFVolkmar Falk
Volkmar Falk
SSSacha P. Salzberg
Sacha P. Salzberg

1 July 2017 in EP Europace
Verified
Journal Article
Closed access
PDF file
ECEtem Caliskan
Etem Caliskan
ASAyhan Sahin
Ayhan Sahin
MYMurat Yilmaz
Murat Yilmaz
BSBurkhardt Seifert
Burkhardt Seifert
RHRicarda Hinzpeter
Ricarda Hinzpeter
MEMaximilian Y. Emmert
Maximilian Y. Emmert
Left atrial appendage (LAA) occlusion has emerged as an interesting alternative to oral anticoagulation (OAC) for stroke prevention in patients with atrial fibrillation (AF). We report the safety, efficacy, and durability of concomitant device-enabled epicardial LAA occlusion during open-heart surgery. In addition to long-term follow-up, we evaluate the impact on stroke risk in this selected population. A total of 291 AtriClip devices were deployed epicardially in patients (mean CHA2DS2-VASc-Score: 3.1 ± 1.5) undergoing open-heart surgery (including isolated coronary artery bypass grafting, valve, or combined procedures) comprising of forty patients from a first-in-man device trial (NCT00567515) and 251 patients from a consecutive institutional registry thereafter. In all patients (n = 291), the LAA was successfully excluded and overall mean follow-up (FU) was 36 ± 23months (range: 1–97 months). No device-related complications were detected throughout the FU period. Long-term imaging work-up (computed tomography) in selected patients ≥5years post-implant (range: 5.1–8.1 years) displayed complete LAA occlusion with no signs of residual reperfusion or significant LAA stumps. Subgroup analysis of patients with discontinued OAC during FU (n = 166) revealed a relative risk reduction of 87.5% with an observed ischaemic stroke-rate of 0.5/100 patient-years compared with what would have been expected in a group of patients with similar CHA2DS2-VASc scores (expected rate of 4.0/100 patient-years). No strokes occurred in the subgroup with OAC. The long-term results from our first-in-man prospective human trial plus our institutional registry of epicardial LAA occlusion with the AtriClip in patients with AF undergoing cardiac surgery demonstrate the safety and durability of the procedure. In addition, our data are suggestive for the potential efficacy of LAA occlusion in reducing the incidence of stroke. If validated in future large randomized trials, routine LAA occlusion in patients undergoing cardiac surgery (with contraindications to treatment with oral anticoagulants) may represent a reasonable adjunct procedure to reduce the risk of future stroke. URL: http://www.clinicaltrials.gov. Unique identifier: NCT00567515.

17 March 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
ZLZhi Li
Zhi Li
ZWZengwei Wang
Zengwei Wang
ZYZongtao Yin
Zongtao Yin
YZYuji Zhang
Yuji Zhang
XXXiaodong Xue
Xiaodong Xue
HWHuishan Wang
Huishan Wang
Gender differences in fibrosis remodeling in patients with long-standing persistent atrial fibrillation

1 September 2013 in Biomaterials
Verified
Journal Article
Closed access
MEMaximilian Y. Emmert
Maximilian Y. Emmert
PWPetra Wolint
Petra Wolint
NWNadine Wickboldt
Nadine Wickboldt
GGGino Gemayel
Gino Gemayel
Benedikt WeberBenedikt Weber
Benedikt Weber
SHSimon P. Hoerstrup
Simon P. Hoerstrup

1 July 2011 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
MEMaximilian Y. Emmert
Maximilian Y. Emmert
SSSacha P. Salzberg
Sacha P. Salzberg
BSBurkhardt Seifert
Burkhardt Seifert
Hector RodriguezHector Rodriguez
Hector Rodriguez
APAndre Plass
Andre Plass
VFVolkmar Falk
Volkmar Falk
Diabetic patients often present with diffuse coronary disease than nondiabetic patients posing a greater surgical challenge during off-pump revascularization. In this study, the safety, feasibility, and completeness of revascularization for this subset of patients was assessed. From 2002 to 2008, 1015 diabetic patients underwent myocardial revascularization. Patients received either off-pump coronary artery bypass (OPCAB; n = 540; 53%) or coronary artery bypass grafting (CABG; n = 475; 47%). Data collection was performed prospectively and data analysis was done by propensity-score (PS)-adjusted regression analysis. Primary endpoints were mortality, major adverse cardiac and cerebrovascular events (MACCEs), and a composite endpoint including major noncardiac adverse events (MNCAEs) such as respiratory failure, renal failure, and rethoracotomy for bleeding was applied. An index of complete revascularization (ICOR) was defined to assess complete revascularization by dividing the total number of distal anastomoses by the number of diseased vessels. Complete revascularization was assumed when ICOR was >1. OPCAB patients had a significantly lower mortality-rate (1.1% vs 3.8%; propensity-adjusted odds ratio (PAOR) = 0.11; p = 0.018) and displayed less frequent MACCE (8.3% vs 17.9%; PAOR = 0.66; p = 0.07) including myocardial infarction (1.3% vs 3.2%; PAOR = 0.33; p = 0.06) and stroke (0.7% vs 2.3%; PAOR = 0.28; p = 0.13). Similarly, a significantly lower occurrence of the noncardiac composite endpoint (MNCAE) (PAOR = 0.46; confidence interval (CI) 95% 0.35-0.91; p < 0.001) was detected. In particular, lesser respiratory failure (0.9% vs 4.3%; PAOR = 0.24; p = 0.63) and pleural effusions (3.3% vs 7.5%; PAOR = 0.45; p = 0.04) occurred, so that fast extubation (≤ 12 h postoperative) was more frequently possible (58.3% vs 34.2%; PAOR = 1.64; p = 0.007). The number of arterial grafts was significantly higher among OPCAB patients (1.54 ± 0.89 vs 1.33 ± 0.81; p = 0.006) due to a more frequent use of the right-internal mammary artery (35.6% vs 22.9%; p < 0.001). ICOR was significantly higher among CABG patients (1.24 ± 0.34 vs 1.30 ± 0.28; p = 0.001). However, for similar proportions in both groups, an ICOR > 1 was achieved clearly indicating complete revascularization (94.3% vs 93.7%; p = 0.24). OPCAB offers a lower mortality and superior postoperative outcomes in diabetic patients with multivessel disease. Arterial grafts are used more frequently that may contribute to better long-term outcomes and the OPCAB approach does not come at the cost of less complete revascularization.